生物活性
AZD8931 (Sapitinib)是一种可逆的,ATP竞争性EGFR, ErbB2和ErbB3抑制剂,IC50分别为4 nM, 3 nM和4 nM,作用于NSCLC细胞比Gefitinib或Lapatinib更有效,作用于ErbB家族比作用于MNK1和Flt选择性强100倍。AZD8931作用于NSCLC和SCCHN 细胞系的效果不同。AZD8931高度选择性作用于 PC-9细胞(EGFR 激活突变型),GI50为0.1 nM,而低活性作用于 NCI-1437细胞,GI50 >10 μM。与lapatinib 或 gefitinib相比,AZD8931作用于 PE/CA-PJ41, PE/CA-PJ49, DOK 和FaDu细胞,更有效作用于p-EGFR, p-erbB2 和 p-erbB3。
化学数据
分子量 | 473.93 |
分子式 | C23H25ClFN5O3 |
CAS号 | 848942-61-0 |
纯度 | >99% |
溶解性(25°C) | DMSO 40 mg/mL |
储存和运输条件 | 固体粉末: -20°C 冷藏长期储存 常温运输及临时存放 |
实验操作 来自于公开的文献,仅供相同实验参考(如实验材料、目的不同,请参考其他文献)
细胞实验 |
---|
细胞系 | a panel of NSCLC and SCCHN cell lines: KYSE-30, OE21, PE/CA-PJ15, PE/CA-PJ34 (clone C12), PE/CA-PJ41 (clone D2), PE/CA-PJ49, DOK, Detroit562, RPMI2650, SCC-4, SCC-9, SCC-25, CAL 27, SW579, FaDu, Hs 840.T, KB, KYSE-450, and HEp-2, HN5; PC-9, Calu-3, NCI-H2073, NCI-H1623, NCI-H522, NCI-H2085, NCI-H2030, NCI-H1703, NCI-H2291, NCI-H2135, NCI-H1975, NCI-H23, NCI-H1650, NCI-H1437, NCI-H3255, and NCI-H1666 cell lines |
方法 | cell viability assay. To determine their antiproliferative activity against cell lines grown in vitro, AZD8931, gefitinib, and lapatinib were tested in a panel of NSCLC and SCCHN cell lines. Cells were incubated for 96 h with a suitable range of concentrations of drug to ensure accurate estimation of the inhibitor concentration required to give 50% growth inhibition (GI50; typically between 0.001-10 μmol/L). Viable cell number was determined by 4 h of incubation with MTS Colorimetric Assay reagent (Promega) and absorbance measured at 490 nm on a spectrophotometer (Molecular Devices). Each experiment was carried out in triplicate for each drug concentration and data are presented as geometric means. Sensitivity groupings of GI50 data were<1 μmol/L (classed as sensitive), 1 to 7 μmol/L (classed as intermediate), and >7 μmol/L (classed as resistant). |
浓度 | 0~10μM |
处理时间 | 96 h |
动物实验 |
---|
动物模型 | BT474c, Calu-3, LoVo, FaDu and PC-9 xenograft mouse models |
配制 | suspended in a 1% (v/v) solution of polyoxyethylenesorbitan monooleate (Tween 80) in deionized water |
剂量 | 6.25-50 mg/kg twice daily |
给药处理 | oral gavage |
不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)
| 小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 |
重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km系数 | 3 | 6 | 12 | 8 | 5 | 20 |
动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
储备液配制
以下数据基于产品分子量,对于特殊产品,请参照COA中的储备液配制条件和说明进行操作。
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.11 mL | 10.5501 mL | 21.1002 mL |
5 mM | 0.422 mL | 2.11 mL | 4.22 mL |
10 mM | 0.211 mL | 1.055 mL | 2.11 mL |